BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 16194130)

  • 1. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
    Spyropoulos AC; Lin J
    J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
    J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
    Wu EQ; Xie J; Wu C; Du EX; Li N; Tan R; Liu Y
    Pharmacoeconomics; 2014 Mar; 32(3):305-13. PubMed ID: 24500859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
    Kahler ZP; Beam DM; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
    Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
    J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
    Spyropoulos AC; Hurley JS; Ciesla GN; de Lissovoy G
    Chest; 2002 Jul; 122(1):108-14. PubMed ID: 12114345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

  • 17. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
    Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
    Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
    Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
    Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study.
    Gustafsson N; Poulsen PB; Stallknecht SE; Dybro L; Paaske Johnsen S
    Eur Heart J Qual Care Clin Outcomes; 2020 Apr; 6(2):130-137. PubMed ID: 31287536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.